MyChart
For more than 15 years, our research team has worked with pharmaceutical sponsors to conduct research in a variety of therapeutic areas under the global banner of auto-immune disorders. Our physician investigators work to bring a wide range of clinical trial opportunities to their patients to include investigational treatments for rheumatoid arthritis, systemic lupus erythematous, psoriatic arthritis, ankylosing spondylitis, giant cell arteritis, polymyalgia rheumatica, osteoporosis, and other conditions. These research trials recruit and enroll participants for oral, injectable, and infusion medications and have resulted in a great number of new and innovative treatments for patients in our clinics, region, and across the country.
Investigators
Research Medical Director
Rheumatology Investigators
- Boise: James Loveless, MD; Marcy Bauer, FNP; Clayton Hawks, FNP; Shannon Lance, DO
- Meridian: Michelle Hicks, FNP; Clayton Hawks, FNP; Woo Young Kim, MD
Contact Us
If you're interested in rheumatology studies at St. Luke’s, please call our clinical research manager at (208) 706-9081 or send us an email.Articles/Publications
- Winthrop KL, Hawkins JA, Weinberg A, Siegel SAR, Baxter JL, Garth K, Huffstutter JE, Loveless J, Ridley D, E Moreta, Messaoudi I, Curtis JR. Immunogenicity of the Recombinant Zoster Vaccine in People with Rheumatoid Arthritis Using Abatacept. Poster presentation at EULAR (European Alliance of Associations for Rheumatology), June 12-15, 2024, Vienna, Austria.
- Sustained Efficacy Responses and a Consistent Safety Profile with Rituximab Repeat Treatment over 5 Years in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors. Keystone E, Cohen S, Emery P, Kremer J, Dougados M, Loveless J, Chung C, Wong P, Lehane P, Tyrrell H. Abstract 1280 November 2012. American College of Rheumatology Annual Meeting, Washington DC.
- Sustained Inhibition of Structural Damage in Patients with Rheumatoid Arthritis and an Inadequate Response to One or More Tumor Necrosis Factor Inhibitors Prior to Rituximab Treatment: 5-Year Data from the REFLEX Study. Keystone E, Cohen S, Emery P, Kremer J, Dougados M, Loveless J, Chung C, Wong P, Lehane P, Tyrrell H. Abstract FRI0183 June 2012. European League Against Rheumatism (EULAR) Annual Meeting.
- Wilson G, Folzenlogen DD. Spondyloarthropathies: New directions in etiopathogenesis, diagnosis, and treatment. Missouri Medicine 2012;109:69-74.
- Wilson GJ, Dyer JA, Folzenlogen DD. Erythema marginatum in a case of post-streptococcal arthralgia: A rash mimicking urticarial. The Internet Journal of Rheumatology, 7(1). DOI:10.5580/e4d.
- Sustained Inhibition of Structural Damage in Patients with Rheumatoid Arthritis and an Inadequate Response to One or More Tumor Necrosis Factor Inhibitors Prior to Rituximab Treatment: 5-Year Data from the REFLEX Study. Keystone E, Cohen S, Emery P, Kremer J, Dougados M, Loveless J, Chung C, Wong P, Lehane P, Tyrrell H. Abstract 2208, November 2011. American College of Rheumatology National Meeting, Chicago, Illinois.
- Evaluation of Clinical Outcomes in Rheumatoid Arthritis (RA) Patients on TNF Blockers in US Community Practice. Ross AS, Conaway D, Loveless J, Chastek B, Becker L, Watson C, Harrison DJ, Gandra SR. Abstract submitted for presentation at European League Against Rheumatism (EULAR) Annual Meeting December 2010.
- A New Methodology to Assess Clinical Change Using Charts in Rheumatoid Arthritis (RA) Patients on TNF Blockers. Bonafede RP, Segal S, Lautzenheiser R, Loveless J, Watson C, Harrison J. Abstract PM 572. Presented at ISPOR 15th Annual International Meeting, May 18, 2010, in Atlanta, Georgia.
- An Open-Label Study of the Safety of Rituximab in Combination with Disease-Modifying Anti-Rheumatic Drugs in Patients with Active Rheumatoid Arthritis (SUNDIAL Stage I). Loveless J, Olech E, Pritchard C, Chai A, Kelman A, Tole S. Abstract 1660, American College of Rheumatology, 2010.
- Perera AC, Lucas M, Rodriquez-Reyna T, Hu P, Steen V, Medsger TA. Clinical Subsets, Skin Thickness Progression and Serum Antibody Levels in Systemic Sclerosis Patients with Anti-Topoisomerase I Antibody. Arthritis and Rheumatism: 2007 Aug; 56(8): 2740 – 2746
Support Local Research Opportunities
Your generosity will change lives.
Give to support laboratory research, patient clinical trials and applied research in our community.